Table 1.
Demographic information of the original cohort.
| Characteristics | N (%) | Groups, n (%) | p Value | ||
|---|---|---|---|---|---|
| Age < 70 (n = 186) | Age ≥ 70 (n = 138) | ||||
| Age (years) | Median ± SD | 68.5 ± 5.3 | 64.8 ± 3.1 | 73.4 ± 3.3 | <0.001 |
| BMI (kg/m2) | Median ± SD | 24.4 ± 3.3 | 24.5 ± 3.4 | 24.3 ± 3.0 | 0.909 |
| BRCA testing | No | 248 (76.5) | 135 (72.6) | 113 (81.9) | 0.051 |
| Yes | 76 (23.5) | 51 (27.4) | 25 (18.1) | ||
| BRCA 1/2 mutation | negative | 60 (78.9) | 40 (78.4) | 20 (80.0) | 0.875 |
| positive | 16 (21.1) | 11 (21.6) | 5 (20.0) | ||
| Performance status | 0 | 253 (79.3) | 151 (83.4) | 102 (73.9) | 0.062 |
| 1 | 65 (20.4) | 29 (16.0) | 36 (26.1) | ||
| 2 | 1 (0.3) | 1 (0.6) | 0 (0.0) | ||
| Hemoglobin (g/L) | ≥110 | 202 (62.3) | 122 (65.6) | 80 (58.0) | 0.331 |
| <110 | 112 (34.6) | 58 (31.2) | 54 (39.1) | ||
| unknown | 10 (3.1) | 6 (3.2) | 4 (2.9) | ||
| Albumin (g/L) | >40 | 144 (47.7) | 90 (51.4) | 54 (42.5) | 0.126 |
| ≤40 | 158 (52.3) | 85 (48.6) | 73 (57.5) | ||
| unknown | 22 (6.8) | 11 (5.9) | 11 (8.0) | ||
| Renal function | >90 | 84 (26.5) | 65 (35.9) | 19 (14.0) | <0.001 |
| (mL/min*1.73 m2) | 60–90 | 186 (58.7) | 105 (58.0) | 81 (59.6) | |
| 30–60 | 45 (14.2) | 11 (6.1) | 34 (25.0) | ||
| 15–30 | 2 (0.6) | 0 (0.0) | 2 (1.5) | ||
| <15 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Neoadjuvant chemotherapy | No | 180 (55.6) | 128 (68.8) | 52 (37.7) | <0.001 |
| Yes | 144 (44.4) | 58 (31.2) | 86 (62.3) | ||
| ASA | 1 | 20 (6.2) | 14 (7.5) | 6 (4.3) | 0.059 |
| 2 | 238 (73.5) | 142 (76.3) | 96 (69.6) | ||
| 3 | 66 (20.4) | 30 (16.1) | 36 (26.1) | ||
| Ascites | <200 mL | 202 (62.3) | 107 (57.5) | 95 (68.8) | 0.038 |
| ≥200 mL | 122 (37.7) | 79 (42.5) | 43 (31.2) | ||
| Tumor dissemination | Low | 108 (33.3) | 62 (33.3) | 46 (33.3) | 0.999 |
| Intermediate | 143 (44.1) | 82 (44.1) | 61 (44.2) | ||
| High | 73 (22.5) | 42 (22.6) | 31 (22.5) | ||
| Surgical complexity score | 1 | 224 (75.3) | 130 (69.9) | 114 (82.6) | 0.009 |
| 2 | 80 (24.7) | 56 (30.1) | 24 (17.4) | ||
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Systemic lymph node dissection | No | 105 (60.2) | 96 (51.6) | 99 (71.7) | <0.001 |
| Yes | 129 (39.8) | 90 (48.4) | 39 (28.3) | ||
| FIGO stage | I | 13 (4.0) | 10 (5.4) | 3 (2.2) | 0.228 |
| II | 32 (9.9) | 21 (11.3) | 11 (8.0) | ||
| III | 229 (70.7) | 124 (66.7) | 105 (76.1) | ||
| IV | 50 (15.4) | 31 (16.7) | 19 (13.8) | ||
| Histology | HGSC | 297 (91.7) | 164 (88.2) | 133 (96.4) | 0.030 |
| EC | 11 (3.4) | 9 (4.8) | 2 (1.4) | ||
| Clear cell | 16 (4.9) | 13 (7.0) | 3 (2.2) | ||
| R0 cytoreduction | No | 185 (57.1) | 102 (54.8) | 83 (60.1) | 0.340 |
| Yes | 139 (42.9) | 84 (45.2) | 55 (39.9) | ||
| CARG | low risk | 209 (64.5) | 157 (84.4) | 52 (37.7) | <0.001 |
| medium risk | 113 (34.9) | 29 (15.6) | 84 (60.9) | ||
| high risk | 2 (0.6) | 0 (0.0) | 2 (1.4) | ||
| Cycles of chemotherapy | Median ± SD | 5.26 ± 1.84 | 5.72 ± 1.67 | 4.64 ± 1.85 | 0.014 |
| Completion of adjuvant chemotherapy | No | 63 (19.4) | 20 (10.8) | 43 (31.2) | <0.001 |
| Yes | 261 (80.6) | 166 (89.2) | 95 (68.8) | ||
| Chemotherapy | none | 2 (0.6) | 0 (0.0) | 2 (1.4) | 0.008 |
| regimen | monotherapy | 5 (1.5) | 0 (0.0) | 5 (3.6) | |
| double therapy | 317 (97.9) | 186 (1.0) | 131 (95.0) | ||
| Hematologic toxicity | I–II | 195 (60.9) | 121 (65.8) | 74 (54.4) | 0.040 |
| III–IV | 125 (39.1) | 63 (34.2) | 62 (45.6) | ||
| Clinical trial | No | 317 (97.8) | 182 (97.8) | 135 (97.8) | 0.989 |
| Yes | 7 (2.2) | 4 (2.2) | 3 (2.2) | ||
| Charlson comorbidity index | mild | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.004 |
| moderate | 35 (10.8) | 28 (15.1) | 7 (5.1) | ||
| sever | 289 (89.2) | 158 (84.9) | 131 (94.9) | ||
HGSC, high-grade serous carcinoma; and EC, endometroid carcinoma.